From NEXT to NICE: From Nanoparticles-based Ex vivo Therapeutics to Nanoparticles-based In vivo Cell Engineering

Time: 3:30 pm
day: Day 1


• Hybrid/polymeric nanoparticles as a solution to improve CAR T-cell manufacturing process and CAR T-cell product attributes.

• Key performance criteria for an ideal in vivo CAR re-infusable product

• Translational hurdles from ex vivo to in vivo CARs